Advertisement

Current Dermatology Reports

, Volume 3, Issue 1, pp 1–5 | Cite as

Current Understanding of the Etiology of Vitiligo

  • Amy Koshoffer
  • Raymond E. BoissyEmail author
Immunology (HC Lima, Section Editor)
  • 767 Downloads

Abstract

This article discusses the current understanding of the etiology of vitiligo. Vitiligo is defined as the loss of pigment-producing cells, melanocytes, from the epidermis of the skin. The onset of vitiligo is believed to require the following three components: (1) a complex of vitiligo susceptibility genes that influence the autoimmune response; (2) genetically abnormal melanocytes; and (3) one or more environmental or physiological factors that induce oxidative stress and activate the genetic program for melanocyte destruction. Melanocytes from vitiligo patients appear to be unable to combat oxidative stress, and so sustain damage. This significant damage could trigger apoptosis in the cells and create an environment rich with cellular fragments that could become autoimmune targets and activate an immune response against melanocytes. Alternatively, oxidatively stressed vitiligo melanocytes could produce cytokines and/or self-antigens to recruit a genetically reactive autoimmune response. Possible therapeutic targets include genes that regulate the immune response, or proteins like iHSP70 that are secreted by the vitiligo cell in response to oxidative stress. Vitiligo is a disease that impacts 1 % of the population and has social, psychological, and sexual ramifications for patients.

Keywords

Vitiligo Melanocyte Autoimmune disorders Hypopigmented lesion Oxidative stress ROS (reactive oxygen species) iHSP70 (inducible heat shock protein 70) 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

A Koshoffer declares no conflicts of interest.

RE Boissy declares no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chadwick S, Heath R, Shah M. Abnormal pigmentation within cutaneous scars: a complication of wound healing. Indian J Plast Surg. 2012;45:403–11.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Tobin DJ. The cell biology of human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24:75–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Taieb A, Picardo M. VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.PubMedCrossRefGoogle Scholar
  4. 4.
    van Geel N, Speeckaert R, Melsens E, et al. The distribution pattern of segmental vitiligo: clues for somatic mosaicism. Br J Dermatol. 2013;168:56–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Hann S, Nordlund JJ, editors. Vitiligo: monograph on the basic and clinical science. 1st ed. Oxford: Blackwell Science Ltd; 2000.Google Scholar
  6. 6.
    Boissy RE, Spritz RA. Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff. Exp Dermatol. 2009;18:583–5.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol. 1988;124:1649–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond). 2011;120:99–120.CrossRefGoogle Scholar
  9. 9.
    Song GG, Kim JH, Lee YH. The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis. Mol Biol Rep. 2013;40:2985–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Jin Y, Ferrara T, Gowan K, et al. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol. 2012;132:1730–3.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Birlea SA, Jin Y, Bennett DC, et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol. 2011;131:371–81.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Cheong KA, Chae SC, Kim YS, Kwon HB, Chung HT, Lee AY. Association of thymic stromal lymphopoietin gene -847C>T polymorphism in generalized vitiligo. Exp Dermatol. 2009;18:1073–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun. 2008;10:244–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Jin Y, Birlea SA, Fain PR, Spritz RA. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol. 2007;127:2558–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356:1216–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003;4:95–104.PubMedCrossRefGoogle Scholar
  17. 17.
    Martinon F, Gaide O, Petrilli V, Mayor A, Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007;29:213–29.PubMedCrossRefGoogle Scholar
  18. 18.
    Guan C, Lin F, Zhou M, et al. The role of VIT1/FBXO11 in the regulation of apoptosis and tyrosinase export from endoplasmic reticulum in cultured melanocytes. Int J Mol Med. 2010;26:57–65.PubMedGoogle Scholar
  19. 19.
    Le Poole IC, Sarangarajan R, Zhao Y, et al. ‘VIT1’, a novel gene associated with vitiligo. Pigment Cell Res. 2001;14:475–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012;132:2601–9.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Brune B, Dehne N, Grossmann N, et al. Redox control of inflammation in macrophages. Antioxid Redox Signal. 2013;19:595–637.PubMedCrossRefGoogle Scholar
  22. 22.
    Slauch JM. How does the oxidative burst of macrophages kill bacteria? Still an open question. Mol Microbiol. 2011;80:580–3.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Fang FC. Antimicrobial actions of reactive oxygen species. MBio. 2011;2(5):e00141-11. doi: 10.1128/mBio.00141-11. Print 2011.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Boissy RE, Liu YY, Medrano EE, Nordlund JJ. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol. 1991;97:395–404.PubMedCrossRefGoogle Scholar
  25. 25.
    Koca R, Armutcu F, Altinyazar HC, Gurel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol. 2004;29:406–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Jain D, Misra R, Kumar A, Jaiswal G. Levels of malondialdehyde and antioxidants in the blood of patients with vitiligo of age group 11–20 years. Indian J Physiol Pharmacol. 2008;52:297–301.PubMedGoogle Scholar
  27. 27.
    Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res. 2009;301:731–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc. 1999;4:91–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Dell’Anna ML, Maresca V, Briganti S, Camera E, Falchi M, Picardo M. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. J Invest Dermatol. 2001;117:908–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Sravani PV, Babu NK, Gopal KV, et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol. 2009;75:268–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Liu L, Li C, Gao J, et al. Promoter variant in the catalase gene is associated with vitiligo in Chinese people. J Invest Dermatol. 2010;130:2647–53.PubMedCrossRefGoogle Scholar
  32. 32.•
    Laddha NC, Dwivedi M, Gani AR, Shajil EM, Begum R. Involvement of superoxide dismutase isoenzymes and their genetic variants in progression of and higher susceptibility to vitiligo. Free Radic Biol Med. 2013;65C:1110–25. The authors report that SOD2 and SOD3 polymorphism are possible genetic risk factors for vitiligo and that these antioxidant isoforms may lead to H2O2 accumulation in critical organelles. CrossRefGoogle Scholar
  33. 33.•
    Laddha NC, Dwivedi M, Mansuri MS, et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol. 2013;22:245–50. This review beautifully describes the major concepts in current vitiligo pathology understanding. PubMedCrossRefGoogle Scholar
  34. 34.
    Boissy RE. Vitiligo. In: Theofilopoulos A, Bona C, editors. The molecular pathology of autoimmunity. 2nd ed. Langhorne: Gordon and Breach/Harwood Academic Publishers; 2001.Google Scholar
  35. 35.
    Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol. 1995;105:683–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Kemp EH, Waterman APGD. Humoral immunity. In: Picardo M, Taieb A, editors. Vitiligo. 1st ed. Berlin: Springer-Verlag; 2010. p. 248–56.Google Scholar
  37. 37.
    Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI. Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med. 1977;297:634–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Bleehen S. Histology of vitiligo. Pigment cell 5. S Karger; 1979:54–61.Google Scholar
  39. 39.
    Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol. 2008;8:663–74.PubMedCrossRefGoogle Scholar
  40. 40.
    Le Poole IC, Van den Wijngaard RM, Verkruisen RP, et al. Foetal human melanocytes: in situ detection, in vitro culture and differentiation characteristics at 6-11 weeks EGA. Pigment Cell Res. 1996;9:126–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 2003;16:254–60.PubMedCrossRefGoogle Scholar
  42. 42.
    van den Boorn J, Konijnenberg D, Dellemijn T, et al. Autoimmune destruction of skin melanocytes by perilesional T-cells from vitiligo patients. J Invest Dermatol. 2009;129:2220–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Le Poole I, Luiten R. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun. 2008;10:227–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Gardner BM, Pincus D, Gotthardt K, Gallagher CM, Walter P. Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb Perspect Biol. 2013;5:a013169.PubMedCrossRefGoogle Scholar
  45. 45.••
    Mosenson JA, Eby JM, Hernandez C, Le Poole IC. A central role for inducible heat shock protein 70 in autoimmune vitiligo. Exp Dermatol. 2013;22:566–9. This paper is one in a series of works that suggest targeting native iHSP70 as a treatment for vitiligo. Targeting iHSP70 may stem the immune response that leads to the destruction of melanocytes. PubMedCrossRefGoogle Scholar
  46. 46.
    Denman CJ, McCracken J, Hariharan V, et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol. 2008;128:2041–8.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations